Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (11-20 of 241) with videos related to

Pageof 25
Sort By:
Lancet (London, England)|August 4, 2009
Raltegravir: a new choice in HIV and new chances for researchSean Emery, Alan Winston
The Lancet. HIV|June 3, 2026
Consideration of brain health in ART interruption studiesAlan Winston, Magnus Gisslen
Brain : a Journal of Neurology|October 12, 2024
Our evolving understanding of the impact of primary HIV infection on brain healthAlan Winston, Merle Henderson
Journal of HIV Therapy|July 9, 2004
The K65R mutation in HIV-1 reverse transcriptaseAlan Winston, Justin Stebbing
Current Opinion in HIV and AIDS|April 18, 2009
Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?Alan Winston, Saye Khoo
The Lancet. HIV|July 5, 2020
Cognitive disorders in people living with HIVAlan Winston, Serena Spudich
The Journal of Antimicrobial Chemotherapy|June 9, 2005
The management of HIV-1 protease inhibitor pharmacokinetic interactionsAlan Winston, Marta Boffito
Ebiomedicine|February 13, 2016
Plasma Biomarkers of HIV-associated Cognitive DiseaseAlan Winston, Jonathan Underwood
Current HIV/AIDS Reports|June 30, 2016
Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive IndividualsJonathan Underwood, Alan Winston
Current Opinion in HIV and AIDS|November 27, 2013
Can antiretroviral therapy prevent HIV-associated cognitive disorders?Alan Winston, Jaime H Vera
Pageof 25

Showing results (11-20 of 241) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|August 4, 2009
Raltegravir: a new choice in HIV and new chances for researchSean Emery, Alan Winston
The Lancet. HIV|June 3, 2026
Consideration of brain health in ART interruption studiesAlan Winston, Magnus Gisslen
Brain : a Journal of Neurology|October 12, 2024
Our evolving understanding of the impact of primary HIV infection on brain healthAlan Winston, Merle Henderson
Journal of HIV Therapy|July 9, 2004
The K65R mutation in HIV-1 reverse transcriptaseAlan Winston, Justin Stebbing
Current Opinion in HIV and AIDS|April 18, 2009
Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?Alan Winston, Saye Khoo
The Lancet. HIV|July 5, 2020
Cognitive disorders in people living with HIVAlan Winston, Serena Spudich
The Journal of Antimicrobial Chemotherapy|June 9, 2005
The management of HIV-1 protease inhibitor pharmacokinetic interactionsAlan Winston, Marta Boffito
Ebiomedicine|February 13, 2016
Plasma Biomarkers of HIV-associated Cognitive DiseaseAlan Winston, Jonathan Underwood
Current HIV/AIDS Reports|June 30, 2016
Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive IndividualsJonathan Underwood, Alan Winston
Current Opinion in HIV and AIDS|November 27, 2013
Can antiretroviral therapy prevent HIV-associated cognitive disorders?Alan Winston, Jaime H Vera
Pageof 25